+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Transgenic activation of the kallikrein-kinin system prevents streptozotocin-diabetic hearts from cardiac fibrosis and left ventricular dysfunction



Transgenic activation of the kallikrein-kinin system prevents streptozotocin-diabetic hearts from cardiac fibrosis and left ventricular dysfunction



European Heart Journal 22(Abstract Suppl.): 54




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035973980

Download citation: RISBibTeXText


Related references

Transgenic expression of kallikrein prevents left ventricular dysfunction and inhibits endothelial induction of ICAM-1 and intramyocardial LFA-1/Mac-1+ infiltration in streptozotocin-induced diabetic cardiopathy in rats. Circulation 104(17 Suppl.): II 198, October 23, 2001

Transgenic activation of the kallikrein-kinin system reduces intramyocardial expression of TNFa and II-1b and improves left ventricular function in experimental diabetic cardiopathy. European Heart Journal 22(Abstract Suppl.): 680, 2001

Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. Faseb Journal 18(7): 828-835, 2004

Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. Faseb Journal 19(14): 2057-2059, 2005

Transgenic expression of human kallikrein prevents altered left ventricular function, the decline in sarcoplasmic reticulum calcium pump activity and the rise in cardiac collagen content in diabetic rats. Circulation 102(18 Suppl.): II 267, October 31, 2000

Transgenic overexpression of insulin-like growth factor I prevents streptozotocin-induced cardiac contractile dysfunction and beta-adrenergic response in ventricular myocytes. Journal of Endocrinology 180(1): 175-182, 2004

The renal kallikrein-kinin system in streptozotocin diabetic rats after ACE-inhibition. Naunyn-Schmiedeberg's Archives of Pharmacology 353(4 SUPPL ): R96, 1996

Increased kallikrein kinin prostaglandin system activity in streptozotocin induced diabetic rats. Diabetes Research & Clinical Practice (SUPPL 1): S583, 1985

Effect of intravenous enkephalin administration of kallikrein kinin system in experimental hemorrhagic shock evidence for activation of kallikrein kinin system by naloxone. Methods & Findings in Experimental & Clinical Pharmacology 10(12): 755-760, 1988

Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. International Journal Of Cardiology. 63(3): 229-235,. 28, 1998

The ginsenoside Rg1 prevents transverse aortic constriction-induced left ventricular hypertrophy and cardiac dysfunction by inhibiting fibrosis and enhancing angiogenesis. Journal of Cardiovascular Pharmacology 62(1): 50-57, 2013

Transgenic expression of human kallikrein prevents sarcoplasmic reticular calcium ion transport dysfunction in diabetic rat heart. Hypertension 36(4): 655, 2000

In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats. Cardiovascular Diabetology 16(1): 80, 2018

Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. Circulation Journal 70(3): 327-334, 2006

Exercise training prevents the development of cardiac dysfunction in the low-dose streptozotocin diabetic rats fed a high-fat diet. Canadian Journal of Physiology and Pharmacology 91(1): 80-89, 2013